Access the full text.
Sign up today, get DeepDyve free for 14 days.
58 N.R. Riding et al. 10. Pelliccia A, Caselli S, Sharma S, Basso C, Bax JJ, Corrado D, D’Andrea A, concentric LV remodelling. The precise significance of these observa- . . D’Ascenzi F, Di Paolo FM, Edvardsen T. European Association of Preventive tions requires a prospective multi-continental longitudinal study in a . Cardiology (EAPC) and European Association of Cardiovascular substantially larger cohort of black athletes. . Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete’s . heart. Eur Heart J 2017;39:1949–1969. 11. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf Supplementary material FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt J-U. Recommendations for Supplementary material is available at European Heart Journal online. . cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1–39.e14. Acknowledgements . 12. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and disqualification recommendations Led by Nelly Khalil, we acknowledge the sterling efforts of Aspetar’s for competitive athletes with cardiovascular abnormalities: preamble, principles, and general considerations. J Am Coll Cardiol 2015;66:2343–2349. athlete screening team in the data collection; Pascal Tahtouh, Farah 13. Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, Casey SA, Sherrid MV. Demachkieh, Nisrine Sawaya, Nancy Karim, Ahmad Alqasim, . Relationship of race to sudden cardiac death in competitive athletes with hyper- Mohammad Mustafa, Ismail Alami, and Ezzoubair Moustaati. trophic cardiomyopathy. J Am Coll Cardiol 2003;41:974–980. 14. Schmied C, Zerguini Y, Junge A, Tscholl P, Pelliccia A, Mayosi B, Dvorak J. . Cardiac findings in the precompetition medical assessment of football players Conflict of interest: none declared. participating in the 2009 African under-17 championships in Algeria. Br J Sports Med 2009;43:716–721. References 15. Di Paolo FM, Schmied C, Zerguini YA, Junge A, Quattrini F, Culasso F, Dvorak J, 1. Harmon KG, Asif IM, Klossner D, Drezner JA. Incidence of sudden cardiac death . Pelliccia A. The athlete’s heart in adolescent Africans: an electrocardiographic in national collegiate athletic association athletes. Circulation 2011;123: and echocardiographic study. J Am Coll Cardiol 2012;59:1029–1036. 1594–1600. 16. Littmann D. Persistence of the juvenile pattern in the precordial leads of 2. Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Terradellas JB, Carre´F, . healthy adult Negroes, with report of electrocardiographic survey on three Guasch E, Heidbuchel H, Gerche AL. Pre-participation cardiovascular evaluation hundred Negro and two hundred white subjects. Am Heart J 1946;32: for athletic participants to prevent sudden death: position paper from the EHRA 370–382. and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. 17. Sheikh N, Papadakis M, Panoulas VF, Prakash K, Millar L, Adami P, Zaidi A, Gati Europace 2016;19:139–163. . S, Wilson M, Carr-White G. Comparison of hypertrophic cardiomyopathy in 3. Papadakis M, Carre F, Kervio G, Rawlins J, Panoulas VF, Chandra N, Afro-Caribbean versus white patients in the UK. Heart 2016; doi: Basavarajaiah S, Carby L, Fonseca T, Sharma S. The prevalence, distribution, and 10.1136/heartjnl-2016-309843. clinical outcomes of electrocardiographic repolarization patterns in male athletes . 18. Sheikh N, Papadakis M, Ghani S, Zaidi A, Gati S, Adami P, Carre ´ F, Schnell F, of African/Afro-Caribbean origin. Eur Heart J 2011;32:2304–2313. Avila P, Wilson M. Comparison of ECG criteria for the detection of cardiac 4. Basavarajaiah S, Boraita A, Whyte G, Wilson M, Carby L, Shah A, Sharma S. abnormalities in elite black and white athletes. Circulation 2014;129:1637–1649. Ethnic differences in left ventricular remodeling in highly-trained athletes rele- 19. Waase MP, Mutharasan RK, Whang W, DiTullio MR, DiFiori JP, Callahan L, vance to differentiating physiologic left ventricular hypertrophy from hypertroph- MancellJ,PhelanD,Schwartz A,Homma S, EngelDJ. Electrocardiographic ic cardiomyopathy. J Am Coll Cardiol 2008;51:2256–2262. . findings in national basketball association athletes. JAMA Cardiol 2018;3: 5. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064–1075. 69–74. 6. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, La Gerche 20. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, Willett D, A, Ackerman MJ, Borjesson M, Salerno JC. International recommendations for . Victor RG. Left ventricular hypertrophy is more prevalent in blacks than whites electrocardiographic interpretation in athletes. Eur Heart J 2018;39:1466–1480. in the general population the Dallas Heart Study. Hypertension 2005;46: 7. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyop- 124–129. athy in Africa. Circulation 2005;112:3577–3583. 21. Ogah OS, Rayner BL. Recent advances in hypertension in sub-Saharan Africa. 8. Keates AK, Mocumbi AO, Ntsekhe M, Sliwa K, Stewart S. Cardiovascular disease in . Heart 2013;99:1390–1397. Africa: epidemiological profile and challenges. Nat Rev Cardiol 2017;14:273–293. 22. Heffernan KS, Jae SY, Wilund KR, Woods JA, Fernhall B. Racial differences in 9. Division UDoEaSAS. Methodology. Standard country or area codes for statistical central blood pressure and vascular function in young men. Am J Physiol 2008; use (M49) https://unstats.un.org/unsd/methodology/m49/ (16 January 2018). . 295:H2380–H2387. doi:10.1093/eurheartj/ehy243 Corrigendum Online publish-ahead-of-print 13 April 2018 ................................................................................................ .................................................................. Corrigendum to: Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipopro- tein(a) particle kinetics [Eur Heart J 2018;39:2577–2585] The authors of the above paper wishes to inform readers that the following changes have been made post-publication: the supplementary data was updated to remove highlighting, the funding section was amended to include: ‘Amgen Inc. funded this study.’, and the conflict of interest section was updated to add: ‘GW has received honoraria for advisory boards and speakers bureau or research grants from Amgen Inc., Sanofi, Regeneron, Kowa, and Genfit; DC, SMM, and PHB have no disclosures; RS, SW, and RS are current or former employees of Amgen Inc. and own Amgen stock/stock options. RS (Somaratne) is an inventor on at least one pending patent application relating to evolo- cumab.’. The paper has now been corrected online. V C Published on behalf of the European Society of Cardiology. All rights reserved. The Author(s) 2018. For permissions, please email: firstname.lastname@example.org.
European Heart Journal – Oxford University Press
Published: Apr 13, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.